Active Ingredient(s): Pomalidomide
FDA Approved: * February 8, 2013
Pharm Company: * CELGENE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Pomalyst Overview

Pomalidomide (INN; marketed as Pomalyst in the U.S.[2] and Imnovid in the EU and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013, by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and ...

Read more Pomalyst Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pomalidomide

Recent Pomalyst Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 1mg, 2mg, 3mg, 4mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Pomalyst: (4 results)

Sorted by National Drug Code
  • 59572-501 Pomalyst 1 mg Oral Capsule by Celgene Corporation
  • 59572-502 Pomalyst 2 mg Oral Capsule by Celgene Corporation
  • 59572-503 Pomalyst 3 mg Oral Capsule by Celgene Corporation
  • 59572-504 Pomalyst 4 mg Oral Capsule by Celgene Corporation

Other drugs which contain Pomalidomide or a similar ingredient: (1 result)

Related Pomalyst Topics:

Started about a year ago after revlimid quit working. Still adjusting the dosage. Gone from 4 to 1 to 2 to 3 mg. Mostly ...

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 29 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA